We are developing the first booster mRNA vaccine against variants of concern of the SARS-CoV-2 coronavirus. Our vaccine is designed to protect against the post-BA.5 omicron descendants now prevalent worldwide, including the BQ.1.1 and XBB.1.5 variants, both responsible for increased transmissibility of COVID-19 and limited efficacy of current vaccines. Our vaccine is also designed to protect against viral dissemination in the brain and the associated neurological and psychological symptoms of long COVID syndrome.
Phylex Biosciences
is a next-generation vaccine company uniquely located at
the crossroads of information technology and biotechnology.
the crossroads of information technology and biotechnology.